Oragenics Announces New Strategic Partnership with Mexico-Based Company, Pharmacos Exakta, S.A. de C.V.

TAMPA, Fla.-- Oragenics, Inc. (OTCQB: OGEN) (OTCBB: OGEN) (the “Company”), a world leader in oral care probiotics, today announced that the Company has entered into a new three year contract agreement with Pharmacos Exakta, S.A. de C.V. Under the terms of the agreement, Pharmacos Exakta will be the exclusive distributor of Oragenics’ oral care probiotics for pets in Mexico under a private label. The pet product will contain ProBiora3®; Oragenics’ patented proprietary blend of three probiotics specifically designed for oral health.

Pharmacos Exakta S.A. de C.V. manufactures and markets ophthalmic and other pharmaceutical products for government and private markets. The company was founded in 1957 and is based in Guadalajara, Mexico. As of February 17, 2010, Pharmacos Exakta S.A. de C.V. operates as a subsidiary of Opko Health, Inc.

"Our strategy is to continue to look for high quality distributors in regions around the world to sell our innovative pet probiotic either under our Evora brand or as a private label. This contract is another step in fulfilling this strategy,” stated John N. Bonfiglio PhD, President and CEO of Oragenics.

About Oragenics, Inc.

Oragenics, Inc. is focused on becoming the world leader in probiotics for oral health for humans and pets and in novel antibiotics against infectious disease. Oragenics, Inc. develops, markets and sells proprietary probiotics specifically designed to enhance oral health for humans and pets, under the brand names Evora® and ProBiora® in over 13 countries worldwide. Oragenics, Inc. has established an exclusive worldwide channel collaboration for lantibiotics, a novel class of broad spectrum antibiotics, with Intrexon Corporation, a synthetic biology company.

For more information, visit www.oragenics.com. Follow Oragenics on Facebook and Twitter.

Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect the Company’s current views with respect to future events and financial performance. These forward-looking statements are based on management’s beliefs and assumptions and information currently available. The words “believe,” “expect,” “anticipate,” “intend,” “estimate,” “project” and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to our ability to raise additional capital to sustain our operations beyond June 30, 2012 and those set forth in our most recently filed annual report on Form 10-K and quarterly report on Form 10-Q, and other factors detailed from time to time in filings with the U.S. Securities and Exchange Commission. We expressly disclaim any responsibility to update forward-looking statements.

For more information visit www.oragenics.com.

Oragenics, Inc.
Corporate Contact
Michael Sullivan, 813-286-7900 x246
Chief Financial Officer
Direct: 813-786-6431
msullivan@oragenics.com
or
LaunchPad IR
Investor Contact
Robert Giordano, 1-800-625-2236 x7770
President
Direct: 917-327-3938
rgiordanonyc@gmail.com

Source: Oragenics, Inc.

Released November 14, 2012